metformin has been researched along with Convalescence in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Convalescence: The period of recovery following an illness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin affects low density lipoprotein (LDL) and high density (HDL) subfractions in the context of impaired glucose tolerance, but its effects in the setting of acute myocardial infarction (MI) are unknown." | 9.22 | Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. ( Connelly, MA; Dullaart, RP; Eppinga, RN; Hartman, MH; Lexis, CP; Lipsic, E; van der Harst, P; van der Horst, IC; van Veldhuisen, DJ, 2016) |
| "Metformin affects low density lipoprotein (LDL) and high density (HDL) subfractions in the context of impaired glucose tolerance, but its effects in the setting of acute myocardial infarction (MI) are unknown." | 5.22 | Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. ( Connelly, MA; Dullaart, RP; Eppinga, RN; Hartman, MH; Lexis, CP; Lipsic, E; van der Harst, P; van der Horst, IC; van Veldhuisen, DJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eppinga, RN | 1 |
| Hartman, MH | 1 |
| van Veldhuisen, DJ | 1 |
| Lexis, CP | 1 |
| Connelly, MA | 1 |
| Lipsic, E | 1 |
| van der Horst, IC | 1 |
| van der Harst, P | 1 |
| Dullaart, RP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III): a Randomized Controlled Trial.[NCT01217307] | Phase 2/Phase 3 | 380 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary efficacy parameter of the GIPS-III trial is LVEF measured by cardiac MRI 4 months after randomization, based on an intention-to-treat analysis. It is hypothesized that metformin therapy will result in a higher ejection fraction after 4 months. (NCT01217307)
Timeframe: 4 months
| Intervention | % of LVEF (Mean) |
|---|---|
| Metformin | 53.1 |
| Placebo | 54.8 |
1 trial available for metformin and Convalescence
| Article | Year |
|---|---|
Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial.
Topics: Aged; Apolipoproteins; Chemotherapy, Adjuvant; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL | 2016 |